Previous 10 | Next 10 |
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO). On Nov. 21, 2022, Merck announced that it had entered into a defini...
REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, ...
NEW YORK, NY / ACCESSWIRE / November 24, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NA...
Investors haven't been happy with the performance of the Nasdaq Composite (NASDAQINDEX: ^IXIC) so far in 2022, with the index firmly in bear market territory despite having seen a significant bounce in recent weeks. The Nasdaq didn't get off to a particularly good start to the new w...
Merck (NYSE: MRK) and Imago Biosciences, Inc. (NASDAQ: IMGO) has reported entry into a definitive agreement where Merck through its subsidiary will acquire Imago for USD 36 per share in cash for a total equity value of USD 1.35 Billion. “We continue to invest in...
Shares of Imago Biosciences Inc ( NASDAQ: IMGO ) opened more than 100% up this morning after Merck & Co Inc ( NYSE: MRK ) said it will acquire the biopharmaceutical firm in a $1.35 billion deal. Imago Biosciences shareholders to get a 105% premium The all-cash agreem...
Acquisition expands Merck’s growing hematology portfolio Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreemen...
Imago BioSciences press release ( NASDAQ: IMGO ): Q3 GAAP EPS of -$0.50 misses by $0.06 . Cash, Cash Equivalents, and Short-Term Investments: As of September 30, 2022, Imago had cash, cash equivalents, and short-term investments of $178.4M compared to $217.4M as o...
- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - - Start-up activities for Bomedemstat pivotal Phase 3 ET and Phase 2 PV trials c...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marr...
News, Short Squeeze, Breakout and More Instantly...
Imago BioSciences Inc. Company Name:
IMGO Stock Symbol:
NASDAQ Market:
NEW YORK, NY / ACCESSWIRE / December 27, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMG...
NEW YORK, NY / ACCESSWIRE / December 23, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Lakeland Bancorp, Inc. (NASDAQ:LBAI)...